Goes to show the level that this management is at , they have a product that is capable of making profit and hear they are still rolling out at invester seminars looking for new investers all the while trying to sell us all down the Pfizer road for a mere 11.5 cents . Where is the talk of new telehealth company sighn ups for our commercial products . Definitely time for this management to go , their miss steps have cost us to much time already .
IF the independent review of the takover is different from their previous acceptance of 11.5 cents then All I'd expect is them trying to save face .
RAP Price at posting:
11.0¢ Sentiment: None Disclosure: Held